• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Corporate News

 Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
0
By Nascent Biotech
In Corporate News
Posted February 23, 2022

Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical

Milestone Payment is the Second of Four in $5M Pritumumab Licensing Deal February 23, 2022, 8:00 am EDT Dateline: Vero Beach Fl, USA Public Company Information: OTCQB: NBIO Vero Beach, Fl USA. – [...]

READ MORE
 Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted January 11, 2022

Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Marble Arch Research Publishes Analyst Research Report on Nascent Biotech
0
By Nascent Biotech
In Corporate News, News
Posted June 15, 2021

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note
0
By Nascent Biotech
In Corporate News
Posted May 4, 2021

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology [...]

READ MORE
 BioPharma Journal: Why Nascent Biotech Inc (OTCMKTS:NBIO) is Worth a Close Look
0
By Nascent Biotech
In Corporate News, News
Posted March 26, 2021

BioPharma Journal: Why Nascent Biotech Inc (OTCMKTS:NBIO) is Worth a Close Look

Nascent Biotech Inc. (OTCMKTS:NBIO) is a clinical stage biopharmaceutical company with a number of potential drivers and catalysts in play. Today, we take a look at recent analysis and [...]

READ MORE
 Nascent Biotech Research Partner, Manhattan BioSolutions, to Present at the ACCESS CHINA Forum at the 2021 JPMorgan Healthcare Conference
0
By Nascent Biotech
In Corporate News, News, Press Releases
Posted January 19, 2021

Nascent Biotech Research Partner, Manhattan BioSolutions, to Present at the ACCESS CHINA Forum at the 2021 JPMorgan Healthcare Conference

SAN DIEGO, CA / ACCESSWIRE / January 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO). Nascent Biotech Research Partner, Manhattan BioSolutions (MABS), Inc. announced that it will be presenting at [...]

READ MORE
 Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer
0
By Nascent Biotech
In Corporate News, News, Press Releases, Science News
Posted December 15, 2020

Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / December 15, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) On December 7, the Company received a letter from the US Food and Drug Administration (FDA) removing a partial [...]

READ MORE
 Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration
0
By Nascent Biotech
In Corporate News, News, Press Releases, Science News
Posted October 20, 2020

Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech” or the “Company”) is pleased to announce that the Company has [...]

READ MORE
 Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars
0
By Nascent Biotech
In Corporate News, News, Press Releases
Posted October 1, 2020

Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars

SAN DIEGO, CA / ACCESSWIRE / October 1, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has continued to reduce its liabilities through stock conversion and payment of accounts [...]

READ MORE
 Nascent Biotech Research Collaboration Partner, Manhattan BioSolutions, Receives Grant for Covid 19 Vaccine Studies
0
By Nascent Biotech
In Corporate News, News, Press Releases
Posted September 24, 2020

Nascent Biotech Research Collaboration Partner, Manhattan BioSolutions, Receives Grant for Covid 19 Vaccine Studies

SAN DIEGO, CA / ACCESSWIRE / September 23, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral [...]

READ MORE
1 2 3 4 5
page 1 of 5
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.